Your browser doesn't support javascript.
loading
COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection.
Lechowicz, Kacper; Drozdzal, Sylwester; Machaj, Filip; Rosik, Jakub; Szostak, Bartosz; Zegan-Baranska, Malgorzata; Biernawska, Jowita; Dabrowski, Wojciech; Rotter, Iwona; Kotfis, Katarzyna.
Afiliação
  • Lechowicz K; Department of Anaesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Drozdzal S; Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Machaj F; Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Rosik J; Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Szostak B; Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Zegan-Baranska M; Department of Anaesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Biernawska J; Department of Anaesthesiology and Intensive Therapy, Pomeranian Medical University, 71-242 Szczecin, Poland.
  • Dabrowski W; Department of Anaesthesiology and Intensive Care, Medical University, 20-090 Lublin, Poland.
  • Rotter I; Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University, 71-210 Szczecin, Poland.
  • Kotfis K; Department of Anaesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, 70-111 Szczecin, Poland.
J Clin Med ; 9(6)2020 Jun 19.
Article em En | MEDLINE | ID: mdl-32575380
ABSTRACT
In December 2019, a novel coronavirus, SARS-CoV-2, appeared, causing a wide range of symptoms, mainly respiratory infection. In March 2020, the World Health Organization (WHO) declared Coronavirus Disease 2019 (COVID-19) a pandemic, therefore the efforts of scientists around the world are focused on finding the right treatment and vaccine for the novel disease. COVID-19 has spread rapidly over several months, affecting patients across all age groups and geographic areas. The disease has a diverse course; patients may range from asymptomatic to those with respiratory failure, complicated by acute respiratory distress syndrome (ARDS). One possible complication of pulmonary involvement in COVID-19 is pulmonary fibrosis, which leads to chronic breathing difficulties, long-term disability and affects patients' quality of life. There are no specific mechanisms that lead to this phenomenon in COVID-19, but some information arises from previous severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS) epidemics. The aim of this narrative review is to present the possible causes and pathophysiology of pulmonary fibrosis associated with COVID-19 based on the mechanisms of the immune response, to suggest possible ways of prevention and treatment.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article